FRCS

The Inner Circle Acknowledges, Divyakant B. Gandhi, MBBS, FRCS, FACS, Circle as a Distinguished Cardiothoracic Surgeon

Retrieved on: 
월요일, 5월 6, 2024
Doctor of Philosophy, Education, Atrial fibrillation, Cardiothoracic surgery, American College, Multimedia, Lung cancer, MBBS, Coronary artery disease, Mentorship, Ohio State University, Ventricular septal defect, Elective surgery, Heart, Parent, Research, University, FACS, Multiple, Lung, Inner circle, McLaren Health Care Corporation, Patient, Medicine, Circulatory system, Physician, Intellectual property, Health, Mitral valve, FRCS, Student, General surgery, Quality of life, Georgia Tech, Medical college, Royal, Royal college

Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.

Key Points: 
  • Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.
  • He has been in practice as a Heart, Lung & Vascular surgeon for over 35 years.
  • As a leader in the clinical setting, Dr. Gandhi is the Chief of Staff, Medical Director, and Chief of Cardiovascular & Thoracic Surgery at McLaren Greater Lansing.
  • Dr. Gandhi practices his specialty under the auspices of the Center for Cardiovascular and Thoracic Surgery in Detroit, MI.

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

Retrieved on: 
토요일, 5월 4, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Stenosis, Administration, Full, Ureteroscopy, Safety, UTUC, American Urological Association, Obstruction, OLYMPUS, Patient, Clutch (eggs), Mitomycins, FRCS, Neoplasm

The study includes a stepwise approach to retrograde administration of JELMYTO and reports that retrograde administration of JELMYTO in the clinic (n=20) produced a 60% complete response rate in patients and ureteral stents were placed in 25% of patients, which is lower than the rate reported in the pivotal OLYMPUS study.

Key Points: 
  • The study includes a stepwise approach to retrograde administration of JELMYTO and reports that retrograde administration of JELMYTO in the clinic (n=20) produced a 60% complete response rate in patients and ureteral stents were placed in 25% of patients, which is lower than the rate reported in the pivotal OLYMPUS study.
  • In the OLYMPUS study 58% (n=41) of patients achieved a complete response, defined as the absence of tumor lesions 3 months after initiation of JELMYTO treatment assessed by urine cytology and ureteroscopy.
  • For additional information about the retrograde administration of JELMYTO, consult the JELMYTO Instructions for Administration accompanying the Full Prescribing Information.
  • Three patients who were unable to tolerate the retrograde approach had antegrade administration of JELMYTO via a nephrostomy tube.

New Study from HSS Reveals Minimally Invasive Procedure Can Delay Arthritis in Select Patients with Hip Impingement

Retrieved on: 
목요일, 4월 18, 2024
Pain, Mechanics, FAI, HSS, Hip, Sports medicine, Hospital for Special Surgery, Hospital, Risk, Osteoarthritis, Femoroacetabular impingement, American Journal, Publishing, Research design, MD, Arthroscopy, Hip pain, Research, Arthritis, Patient, Paper, MBA, Philip, FRCS, Joint capsule, Friction, Arthroplasty

NEW YORK, April 18, 2024 /PRNewswire/ -- A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis. The retrospective study, published online on March 8, 2024, in The American Journal of Sports Medicine, is the first to link hip arthroscopy with a reduced risk of developing hip arthritis over the long term.

Key Points: 
  • Hip impingement occurs when the bones of the hip joint are not shaped properly, causing them to rub against one another.
  • Prior studies have shown that 85-90% of patients with hip impingement who undergo modern arthroscopy return to their usual activity level.
  • "By contrast, we studied the effect of modern arthroscopic methods by comparing the degree of arthritis in each patient's operative hip versus their nonoperative hip.
  • For ideal candidates, the evidence shows that hip arthroscopy may delay or prevent arthritis for one in four patients.

Changing Paradigm For Physicians Demonstrates Value of Leadership Training

Retrieved on: 
월요일, 4월 15, 2024
Education, Physician, Organization, Hospital, Certification, Health, MD, PLDP, Research, FACS, Literature, AAPL, CPE, Failure, FRCS, Overalls

WASHINGTON, April 15, 2024 /PRNewswire/ -- A new study by the American Association for Physician Leadership (AAPL) identifies how the changing role of physicians reveals the need for expanded leadership training to meet the demand of providing quality healthcare.

Key Points: 
  • "The share of physicians working in practices wholly owned by physicians dropped to 46.7%, down from 60.1% in 2012," according to research cited in the white paper.
  • Physicians do not typically acquire leadership and management skills during their medical training; however, a growing array of leadership development opportunities, including those through certification and those offering a variety of content, format, duration, and purpose have emerged to meet the demand.
  • AAPL looks forward to helping drive further expansion in this critical area of physician training and education."
  • These programs, the research found, are highly dependent on the overall culture and commitment to leadership training within organizations inside each sector of healthcare.

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
수요일, 3월 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity

Retrieved on: 
수요일, 3월 27, 2024
Health, African Americans, Risk, Family, Historical trauma, AI, NIH, Treatment, OTC, MPH, FAAFP, FRCS, Artificial intelligence, Medical device

Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families.

Key Points: 
  • Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families.
  • The historical trauma and systemic bias common in African American communities can limit the amount of information known about the health of relatives.
  • Without better methods for capturing information, existing health disparities addressing prevention and risk can persist.
  • The Company held multiple focus groups with African American doctors and community members to help develop and prototype culturally sensitive approaches to collecting information about family health.

New Book Explores the Evolution of a Physician Leader

Retrieved on: 
금요일, 4월 5, 2024
Knowledge, Community, Altruism, FRCS, FACS, Physician, Collection, Management

WASHINGTON, April 5, 2024 /PRNewswire/ -- The American Association for Physician Leadership has published a new book by its president and CEO Peter Angood, MD, FRCS (C), FACS, MCCM, FAAPL(Hon), Inspiring Growth and Leadership in Medical Careers: Transform Healthcare as a Physician Leader.

Key Points: 
  • The book details a career journey for physicians who are moving toward becoming experienced leaders.
  • The sections of the book describe the phases of evolution into leadership: Beginnings, Knowledge of Healthcare Environment, Professionalism, Community and Relationship Management, Business Skills and Knowledge, Leadership, and Growth to Move Forward.
  • "Being a physician is an opportunity to emulate the traits of a leader in the community.
  • One does not need formal titled roles and a load of administrative responsibility to be recognized as a leader.

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

Retrieved on: 
월요일, 3월 18, 2024
Harvard Medical School, Worldwide, Research, Doctor of Philosophy, Protein, Regius Professor, Skin, Secretome, Safety, FACS, FRCS, BLA, Peptide, Vaccine

Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.

Key Points: 
  • Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.
  • Carmell’s technology was previously being developed as a BLA and has Phase 2 human clinical data supporting safety and efficacy.
  • In comparison, other aesthetic products feature 1-2 synthetic proteins with sparse evidence of clinical efficacy.
  • Carmell aims to launch a limited-edition product this month followed by 9 other skincare products over the summer 2024.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
화요일, 3월 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Retrieved on: 
화요일, 2월 27, 2024
Interventional oncology, University College London, Division, FRCS, Magnetic resonance, Prostate cancer, MD, Temperature, UCL, TSX, Surgeon, BPH, Prostate, Patient, Helium, Diagnosis, Deep learning, Claustrophobia, Workflow, Siemens Healthineers, MRI, Cancer, Partnership, Medical imaging

TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.

Key Points: 
  • TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
  • At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
  • I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
  • We look forward to collaborating with Profound to help expand access to TULSA as well.